Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
May 16, 2021Open Access

The Spike Proteins of SARS-CoV-2 B.1.617 and B.1.618 Variants Identified in India Provide Partial Resistance to Vaccine-elicited and Therapeutic Monoclonal Antibodies

View Full Paper
Ask AI
Bookmark
Share

Authors

TTTakuya TadaNew York UniversityHZHao ZhouYunnan UniversityBDBelinda M. DcostaNew York University

Discussion

Loading...

Member takes

Implication

Key Points

Key points are not available for this paper at this time.

Cite This Study

Tada et al. (2021) studied this question.

synapsesocial.com/papers/6a9e5074100e5eefddacb813https://doi.org/10.1101/2021.05.14.444076
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Decreased neutralization of SARS-CoV-2 global variants by therapeutic anti-spike protein monoclonal antibodies2021 · 76 citations
  2. 2Convergent evolution of SARS-CoV-2 spike mutations, L452R, E484Q and P681R, in the second wave of COVID-19 in Maharashtra, India2021 · 268 citations
  3. 3Deep Mutational Scanning of SARS-CoV-2 Receptor Binding Domain Reveals Constraints on Folding and ACE2 Binding2020 · 2,267 citations
  4. 4Adaptation of SARS-CoV-2 in BALB/c mice for testing vaccine efficacy2020 · 851 citations
  5. 5An ACE2 Microbody Containing a Single Immunoglobulin Fc Domain Is a Potent Inhibitor of SARS-CoV-22020 · 87 citations